Amylgen’s Articles & Posters

2018/02/19

Neuroprotective effect of a new photobiomodulation technique against Aβ25–35 peptide–induced toxicity in mice: Novel hypothesis for therapeutic approach of Alzheimer’s disease suggested

Amylgen’s murine model demonstrates the efficacy of RegenLife ’s device application for the treatment of Alzheimer’s disease   Regenlife is opening doors to new treatment options for Alzheimer’s […]
2015/01/20

Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25-35 peptide-injected mice, a nontransgenic Alzheimer’s disease model

  Authors: Lahmy V1, Long R2, Morin D2, Villard V3, Maurice T1 1Inserm U 710, University of Montpellier 2 Montpellier, France ; Amylgen, Montferrier-sur-Lez France. 2Inserm […]
2015/01/09

The Effects of Sigma-1 Receptor Selective Ligands on Muscarinic Receptor Antagonist Induced Cognitive Deficits in Mice

  Authors: Malik M1, Rangel-Barajas C, Sumien N, Su C, Singh M, Chen Z, Huang RQ, Meunier J, Maurice T, Mach RH, Luedtke RR. 1University of North […]
2015/01/08

Combining two repurposed drugs as a promising approach for Alzheimer’s disease therapy.

Authors: Ilya Chumakov1, Serguei Nabirotchkin1, Nathalie Cholet1, Aude Milet1, Aurélie Boucard1, Damien Toulorge1, Yannick Pereira1, Esther Graudens1, Sory Traoré1, Julie Foucquier1, Mickael Guedj1, Emmanuel Vial1, Noëlle […]